

**National Coverage Determination**  
**Procedure Code: 86301**  
**Tumor Antigen by Immunoassay CA 19-9**  
**CMS Policy Number: 190.30**  
[Back to NCD List](#)

**Description:** Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade. This policy specifically addresses the following tumor antigen: CA19-9.

**Indications:**

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.

Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma. The test is not indicated for diagnosing these two diseases.

**Limitations:**

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

---

To review all requirements of this policy, please see: [CMS NCD listing by Chapter](#)

**Covered ICD-10 Codes.**

ICD-10	Descriptor
<a href="#">C22.1</a>	Intrahepatic bile duct carcinoma
<a href="#">C23</a>	Malignant neoplasm of gallbladder
<a href="#">C24.0</a>	Malignant neoplasm of extrahepatic bile duct
<a href="#">C24.1</a>	Malignant neoplasm of ampulla of Vater
<a href="#">C24.8</a>	Malignant neoplasm of overlapping sites of biliary tract
<a href="#">C24.9</a>	Malignant neoplasm of biliary tract, unspecified
<a href="#">C25.0</a>	Malignant neoplasm of head of pancreas
<a href="#">C25.1</a>	Malignant neoplasm of body of pancreas
<a href="#">C25.2</a>	Malignant neoplasm of tail of pancreas
<a href="#">C25.3</a>	Malignant neoplasm of pancreatic duct
<a href="#">C25.4</a>	Malignant neoplasm of endocrine pancreas
<a href="#">C25.7</a>	Malignant neoplasm of other parts of pancreas
<a href="#">C25.8</a>	Malignant neoplasm of overlapping sites of pancreas
<a href="#">C25.9</a>	Malignant neoplasm of pancreas, unspecified
<a href="#">C78.7</a>	Secondary malign neoplasm of liver and intrahepatic bile duct
<a href="#">C78.80</a>	Secondary malignant neoplasm of unspecified digestive organ
<a href="#">C78.89</a>	Secondary malignant neoplasm of other digestive organs
<a href="#">D37.6</a>	Neoplasm of uncertain behavior of liver, GB & bile duct
<a href="#">D37.8</a>	Neoplasm of uncertain behavior of oth digestive organs
<a href="#">D37.9</a>	Neoplasm of uncertain behavior of digestive organ, unsp
<a href="#">G89.3</a>	Neoplasm related pain (acute) (chronic)
<a href="#">M33.03</a>	Juvenile dermatomyositis without myopathy
<a href="#">M33.13</a>	Other dermatomyositis without myopathy
<a href="#">M33.93</a>	Dermatopolymyositis, unspecified without myopathy
<a href="#">R97.8</a>	Other abnormal tumor markers
<a href="#">Z85.068</a>	Personal history of malignant neoplasm of small intestine
<a href="#">Z85.07</a>	Personal history of malignant neoplasm of pancreas
<a href="#">Z85.09</a>	Personal history of malignant neoplasm of digestive organs

The content and format of the following files and/or webpages are copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All recipients of these files agree not to distribute, reproduce and/or use the information contained within, in any manner not expressly agreed upon by the user and Wheaton Partners, LLC - dba CodeMap®.

All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. Both CMS and Medicare contractor coverage policy information may change at any time. CodeMap® makes no representation, warranty, or guarantee that this compilation of coverage policy information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

